Compare Novo Nordisk A/S (NVO) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Short Term Corporate Bond ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Novo Nordisk A/S is far larger — about 3.2× Vanguard Short Term Corporate Bond ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vanguard Short Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| NVO | VCSH | |
|---|---|---|
Market Cap | $165.31B | $51.90B |
Volume | 11,432,838 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $80.20 |
52-Week Low | $35.29 | $77.03 |
Typical Hold Time | 116 Days | 52 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.34 with a slight 0.09% daily gain. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its competitive 4.5% dividend yield and low 0.03% expense ratio, though some analysts note tight credit spreads and downgrade it to 'Hold'. The fund's short 2.7-year duration minimizes interest rate risk but carries corporate credit exposure.
The ETF offers a higher yield than treasury alternatives but faces headwinds from limited price appreciation potential amid rising rates and compressed spreads. Key risks include credit deterioration and institutional selling. Analyst sentiment is mixed, balancing yield appeal against near-term unattractive entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
